Advances on the role of the deleted in breast cancer (DBC1) in cancer and autoimmune diseases

Qiannan Fang; Joseph A Bellanti; Song Guo Zheng

doi:10.1002/JLB.6MR0320-086R

Advances on the role of the deleted in breast cancer (DBC1) in cancer and autoimmune diseases

J Leukoc Biol. 2021 Feb;109(2):449-454. doi: 10.1002/JLB.6MR0320-086R. Epub 2020 Apr 26.

Authors

Qiannan Fang^{1

2}, Joseph A Bellanti³, Song Guo Zheng²

Affiliations

¹ Department of Clinical Immunology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
² Department of Internal Medicine, Ohio State University College of Medicine and Wexner Medical Center, Columbus, Ohio, USA.
³ Department of Pediatrics and Microbiology-Immunology, Georgetown University Medical Center, Washington, District of Columbia, USA.

PMID: 32337788
DOI: 10.1002/JLB.6MR0320-086R

Abstract

DBC1 (deleted in breast cancer 1) is a human nuclear protein that modulates the activities of various proteins. Most of the research on DBC1 has focused on metabolism and epigenetics because it is a crucial endogenic inhibitor of deacetylase Sirtuin1 (SIRT1). In this review, we have discussed and summarized the new advances in DBC1 research, mostly focusing on its structure, regulatory function, and significance in cancer and autoimmune diseases.

Keywords: DBC1; SIRT1; autoimmune diseases; cancer.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Adaptor Proteins, Signal Transducing / chemistry
Adaptor Proteins, Signal Transducing / metabolism*
Animals
Apoptosis
Autoimmune Diseases / metabolism*
Humans
Lymphocytes / metabolism
Neoplasms / metabolism*
Protein Binding

Substances

Adaptor Proteins, Signal Transducing

Abstract

Publication types

MeSH terms

Substances

Grants and funding